Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan vs Endocrine Therapy in HR+/HER2-low Advanced Breast Cancer
NCT06837792Phase 2Recruiting
- Sponsor
- Yonsei University
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by Yonsei University. Started Oct 2023; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06837792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837792.